SANUWAVE Health, Inc. is an emerging leader in the development and commercialization of a high- energy, focused, shock wave technology that is used in devices for the repair and regeneration of bones, muscles, tendons and skin, and for the separation of solids and fluid in non-medical systems. Within healthcare, SANUWAVE’s proprietary, patented Pulsed Acoustic Cellular Expression (PACE) technology emits high-energy, acoustic shock waves based upon electrohydraulic principles that restore the body’s normal healing processes. This activates biologic signaling which leads to tissue repair and regeneration and blood vessel growth – revascularization and microcirculatory enhancement. SANUWAVE has three devices that employ the PACE technology. The lead device for the global wound care market, the dermaPACE® System, is cleared by FDA for the treatment of Diabetic Foot Ulcers. The dermaPACE System is CE Marked in Europe for advanced wound care indications. Additionally, dermaPACE and wound indications are currently licensed or approved in Canada, Australia, New Zealand, and South Korea. The orthoPACE® device is CE Marked for orthopedic and musculoskeletal indications. OssaTron®, the Company’s legacy device, is approved by the FDA for multiple orthopedic conditions which have failed to respond to conservative treatment. In addition, SANUWAVE has patented the use of its shock wave technology in non-medical fields, including energy (improved/enhanced oil recovery), water (purification), food (bacterial reduction), biofilm removal and industrial effluent (particulate separation). SANUWAVE has started confirmatory testing on water cleaning and biofilm removal with successful results and is working toward licensing/partnership relationships.